Conţinutul numărului revistei |
Articolul precedent |
Articolul urmator |
160 4 |
Ultima descărcare din IBN: 2024-04-15 15:07 |
Căutarea după subiecte similare conform CZU |
[616.98:578.834.1]-085.2 (1) |
Boli transmisibile. Boli infecţionase şi contagioase, stări febrile (586) |
Virologie (446) |
SM ISO690:2012 COJOCARU, Stela, RUSSU, Irina, BUTA, Galina, BERSAN, Sebastian, POTÎNG-RAŞCOV, Valentina, CULIUC, Natalia, BABA, Lilia. A reduced fixed dose of tocilizumab 200 mg compared to 400 mg in patients with severe COVID-19 disease. In: One Health and Risk Management, 2023, nr. 4(4), pp. 19-26. ISSN 2587-3458. DOI: https://doi.org/10.38045/ohrm.2023.4.02 |
EXPORT metadate: Google Scholar Crossref CERIF DataCite Dublin Core |
One Health and Risk Management | ||||||
Numărul 4(4) / 2023 / ISSN 2587-3458 /ISSNe 2587-3466 | ||||||
|
||||||
DOI:https://doi.org/10.38045/ohrm.2023.4.02 | ||||||
CZU: [616.98:578.834.1]-085.2 | ||||||
Pag. 19-26 | ||||||
|
||||||
Descarcă PDF | ||||||
Rezumat | ||||||
Introduction. Excessive, deregulated pro-inflammatory cytokine secretion has a detrimental impact on the evolution of COVID-19, aggregating the tissue impairment, organ failure, and an increased risk of death. Several studies have demonstrated the beneficial effect of Tocilizumab (TCZ) in reducing hyperimmune response in severe forms of COVID-19. Material and methods. This is an experimental controlled clinical trial, consisting of 66 patients hospitalized with severe COVID-19. Results. On overage, the decision to administer TCZ was made on average on the 11.34±0.31 day of the disease, when the beginning of Cytokine Storm was suspected in the patients already on dexamethasone treatment. The clinical and paraclinical parameters, including fever, asthenia and dyspnea duration, SpO2 level, oxygen therapy need, improvement of the radiological picture, and duration of hospitalization were more favorable in patients treated with TCZ 400 mg compared to those treated with TCZ 200 mg (p<0.0001). The relative risk of rapid worsening after TCZ (RR=0.88), the relative risk of decreasing blood pressure (RR=0.29) and the relative risk of transfer to intensive care units for invasive or non-invasive ventilation (RR=0.8) was lower in patients treated with TCZ 200 mg compared to the 400 mg TCZ lot. Conclusions. The dose of TCZ had a significant impact on the duration of clinical manifestations, the duration of oxygen therapy and the duration of patient hospitalization, with better results for TCZ 400 mg compared to TCZ 200 mg. Although the risk of worsening after TCZ and the risk of transfer to intensive care were lower in patients treated with TCZ 200 mg. So, the 200 mg fixed dose of TCZ can be a life-saving option for severely ill patients with COVID-19 in the context of IL-6 inhibitor supply shortages. |
||||||
Cuvinte-cheie COVID-19, cytokine storm, Tocilizumab, severe forms, oxygen therapy, COVID-19, furtună de citokine, tocilizumab, forme severe, terapie cu oxigen |
||||||
|